RBC: 'we expect to see a negative impact to VRDN's shares', Shares 24% Today
Tweet Send to a Friend
RBC Capital analyst Lisa Walter reiterated an Outperform rating and $42.00 price target on Viridian Therapeutic (NASDAQ: VRDN).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
